Linezolid Rowex 2 mg/ml solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

linezolid rowex 2 mg/ml solution for infusion

rowex ltd - linezolid - solution for infusion - 2 milligram(s)/millilitre - other antibacterials; linezolid - other antibacterials - it is indicated for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria and for the treatment of complicated skin and soft tissue infections

LINEZOLID SANDOZ linezolid 600 mg/300 mL injection IV infusion bag Australia - English - Department of Health (Therapeutic Goods Administration)

linezolid sandoz linezolid 600 mg/300 ml injection iv infusion bag

sandoz pty ltd - linezolid, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: citric acid; sodium hydroxide; sodium citrate dihydrate; water for injections; hydrochloric acid; glucose monohydrate - linezolid sandoz is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics,including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected

LINEZOLID INJECTION SOLUTION Canada - English - Health Canada

linezolid injection solution

sandoz canada incorporated - linezolid - solution - 2mg - linezolid 2mg - oxazolidinones

LINEZOLID injection, solution United States - English - NLM (National Library of Medicine)

linezolid injection, solution

sandoz inc - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 200 mg in 100 ml - linezolid is indicated for the treatment of nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and - resistant isolates) or streptococcus pneumoniae [see clinical studies (14)]. linezolid is indicated for the treatment of community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14)]. linezolid is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or streptococcus agalactiae . linezolid injection has not been studied in the treatment of decubitus ulcers [see clinical studies (14)]. linezolid is indicated for the treatment of uncomplicated skin and skin structure infections caused by staphylococcus aureus (methicillin-susceptible isolates

LINEZOLID SZ linezolid 600 mg/300 mL injection IV infusion bag Australia - English - Department of Health (Therapeutic Goods Administration)

linezolid sz linezolid 600 mg/300 ml injection iv infusion bag

sandoz pty ltd - linezolid, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: citric acid; sodium hydroxide; sodium citrate dihydrate; water for injections; hydrochloric acid; glucose monohydrate - linezolid sz is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics,including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected

Linezolid 600mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

linezolid 600mg tablets

sandoz ltd - linezolid - oral tablet - 600mg

LINEZOLID SANDOZ 2 mg/ml INFUSION (PARENTERAL) South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

linezolid sandoz 2 mg/ml infusion (parenteral)

sandoz south africa (pty) ltd - infusion (parenteral) - see ingredients - each 1,0 ml solution contains : linezolid 2,0 mg

LINEZOLID powder, for suspension United States - English - NLM (National Library of Medicine)

linezolid powder, for suspension

hikma pharmaceuticals usa inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 100 mg in 5 ml - linezolid is indicated for the treatment of nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14)]. linezolid is indicated for the treatment of community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies ( 14)]. linezolid is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or streptococcus agalactiae . linezolid has not been studied in the treatment of decubitus ulcers [see clinical studies (14)]. linezolid is indicated for the treatment of uncomplicated skin and skin structure infections caused by staphylococcus aureus (methicillin-susceptible isolates only) or

LINEZOLID tablet United States - English - NLM (National Library of Medicine)

linezolid tablet

novel laboratories, inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg - linezolid tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid tablets are not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4)] . nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14)] . community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14)] . complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyo

LINEZOLID tablet, film coated United States - English - NLM (National Library of Medicine)

linezolid tablet, film coated

zydus pharmaceuticals usa inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg - linezolid tablet is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid tablet is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogen